Dela

Om oss

We are ScandiDos – an innovative forward-thinking company with groundbreaking software and hardware solutions for patient quality assurance in modern radiation therapy.

Citat

When implementing the Accuray Radixact® with Synchrony®, it became obvious to us to invest in the Delta4 HexaMotion. This solution was the best choice in order to control treatments of moving targets with excellent precision. In partnership with ScandiDos, we will act as a reference center for the Delta4 HexaMotion. We have been performing IMRT / VMAT treatments since 2011 as well as stereotaxy treatments on various machines. The advantage of the Delta4 is that it is a detector that is compatible with all these equipment. Its 3D representation of the measured dose is a real advantage. We find in Scandidos products what could characterize the Nordic spirit: simple and effective!
Esther Bouche, Physics Team Manager – Medical Physicist
We at ScandiDos are very impressed with the extraordinary cancer care being delivered at Pôle d’Imagerie et de Cancérologie du Pont Saint Vaast and are proud to be supporting them with tools to secure the highest level of quality in their radiotherapy treatments. The solutions we have developed specifically for QA of moving targets with our Delta4 Phantom+ coupled with HexaMotion have been very well received by the market and we look forward to cooperate with Pôle d’Imagerie et de Cancérologie du Pont Saint Vaast to continue to develop our solutions.
Gustaf Piehl, President & CEO of ScandiDos
We chose to work with ScandiDos for our internal testing of the Synchrony® feature for the Radixact® System because they have a robust solution for comprehensive quality assurance of moving targets. We have found the Delta4 Phantom+ and the Delta4 HexaMotion to be convenient, accurate, and easy to use.”
Dylan Casey, Ph.D., Director, Medical Physics & Systems Analysis at Accuray Incorporated
We are proud of our close cooperation with Accuray, and that we can fulfill their extensive demands on Quality Assurance for treatments with moving targets. With ScandiDos’ solutions, Delta4 Phantom+ and Delta4 HexaMotion, we are simplifying the implementation of this novel technique for Accuray’s customers. We’re looking forward to supporting them in their important work.
Gustaf Piehl, CEO at ScandiDos
We are very much looking forward to use the MR-compatible Delta4 Phantom+ at our Viewray MRIdian Linac as well as at our Elekta and Tomotherapy Linacs to further advance and streamline our patient QA.
Sebastian Klüter, PhD , Medical Physicist, Department of Radiation Oncology, Heidelberg University Hospital, Germany
The Delta4 Phantom+ MR is quick and easy to use and gives us confidence that our treatments are delivered just as intended.
Wilfred de Vries, Clinical physicist engineer, UMC Utrecht, The Netherlands
Under året har ScandiDos ytterligare stärkt sin ställning vad gäller försäljning av spetsprodukter där vår HexaMotion, i det kommande segmentet 4DRT (4-Dimensional Radiation Therapy), valts av de ledande universitetssjukhusen.
Görgen Nilsson, VD
C-Rad har börjat marknadsföra sin bilddetektor inom området kvalitetssäkring och kommer därmed att erbjuda nedströms dosimetri. Vi måste därmed se C-Rad som en konkurrent till ScandiDos och avslutar därför säljsamarbetet i Nordamerika.
Görgen Nilsson, VD ScandiDos
ScandiDos har sedan 6 år tillbaka en väl fungerande organisation i USA med huvudkontor i Madison som ansvarar för försäljning och mycket uppskattad service-support till en relativt stor kundbas. Med denna organisation kommer vi nu åter att fokusera till 100% på ScandiDos egna produkter.
Görgen Nilsson, VD ScandiDos
- Detta är en betydande milstolpe för oss. Japan har under många år varit den enskilt viktigaste marknaden för ScandiDos och den här ordern är ett kvitto för oss att vårt system motsvarar kraven hos de kvalitetsmedvetna japanska kunderna som alltid ställer höga krav
Görgen Nilson
Genom den förestående emissionen i samband med listning på NASDAQ OMX First North stärker vi vår finansiella ställning och får de resurser vi behöver för vår tillväxtsatsning. Att marknadsansluta vår aktie är ett naturligt steg för ScandiDos. Som publikt bolag kommer vi att f6 bättre frihetsgrader att vidareutveckla bolaget både organiskt och via förvärv
Görgen Nilsson, VD ScandiDos

Prenumerera